Investor Presentation Full Year 2021
10
Investor presentation Full year 2021
Obesity care sales grew by 55% for the full year 2021
Reported sales split in operational units
Branded AOM TRX in the US
DKK billion
TRX count (000s)
3
42%1
3%1
55%
90%
48
78%
2.4
1.8
1.2
0.6
40
60%
32
24
30%
16
8
41.7
21.9
10.0
0
0%
0
2019
2020
2021
Jan
Jan
Jan
2019
2020
2021
Jan
2022
INAO
IO
-Market share (RHS)
SaxendaⓇ
Branded AOM Market
Growth at CER
-
WegovyⓇ
1 Annual growth at CER. Each TRX data points represents one week of data
NAO: North America operations, IO: International operations, RHS: Right hand side axis, Rx: Prescriptions
Note: Sales growth at constant exchange rates; AOM: Anti-Obesity Medications (includes Wegovy®, Saxenda®, Qsymia and Contrave),
Source: IQVIA NPA - TRX data, Weekly (ending 14 January 2022)
WegovyⓇ launch in the US
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
Novo NordiskⓇ
~22,000 weekly Rx 32 weeks after launch
Commercial formulary access around more
than 70%, with >70% of WegovyⓇ script new
to the AOM class
Commitment to the people living with
obesity and potential of WegovyⓇ remain
unchangedView entire presentation